New data from the Phase 3 BRAVE-AA-PEDS trial highlights baricitinib’s strong performance in adolescents facing severe alopecia areata. Incyte (INCY) and Eli Lilly now plan to pursue global approvals ...
Incyte (INCY) shares have shown solid momentum over the past month, gaining 12% and delivering a 21% return over the past 3 months. The company continues to draw investor attention for its performance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback